IL13RA2 and neoplasm: The extent of the improvement provided by checkpoint inhibitors appears to be contingent upon the specific CAR-T-cell utilized, as CAR-T cells directed against EGFRvIII and IL13Rα2 each promoted distinct immune checkpoint environments within their respective tumor settings [18].